• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    2/25/26 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALEC alert in real time by email

    Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer's Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer's Disease)

    Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer's disease expected in the first half of 2026

    $256.0 million in cash, cash equivalents and investments provide runway at least through 2027

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported fourth quarter and full year 2025 financial results and recent portfolio and business updates. As of December 31, 2025, Alector's cash, cash equivalents, and investments totaled $256.0 million.

    "Alector's strength lies in the combination of a highly differentiated blood-brain barrier platform and a team with deep experience executing complex neurodegenerative programs," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "Following more than six years of focused investment in our ABC technology, we believe the breadth, flexibility, and tunability of our ABC platform position us to translate scientific innovation into exciting clinical-stage assets. At the same time, we continue to advance the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer's disease, together with GSK, toward an independent interim futility analysis in the first half of 2026."

    Recent Program Updates

    Alector Brain Carrier (ABC): Preclinical and Research Pipeline

    Alector's pipeline leverages its proprietary blood-brain barrier platform, Alector Brain Carrier (ABC), which has been developed to enhance the delivery of therapeutics to the brain. ABC is designed to enable peripheral dosing and is adaptable across multiple drug modalities, including antibodies, enzymes, and siRNA.

    Built on core design principles of versatility, optimized binding properties, and translatability, ABC is intended to enable targeted brain delivery with improved safety and efficacy. ABC-enabled candidates have demonstrated robust brain penetration in preclinical studies, providing the basis for advancing multiple programs targeting neurodegenerative diseases.

    AL137

    • Alector continues to advance AL137, its lead ABC-enabled anti-amyloid beta (Aβ) antibody for the treatment of AD, through investigational new drug (IND)-enabling studies. The company expects to file an IND application in Q4 2026 / Q1 2027, based on the timing of GMP clinical supply production.



    • AL137 is engineered for optimal brain uptake, potency, safety, and convenience. The candidate comprises a high-affinity, fully human antibody that selectively binds PyroGlu3, a validated epitope on toxic amyloid beta found in plaques and retains an active effector function intended to facilitate myeloid-mediated plaque clearance. AL137 incorporates Alector's proprietary ABC technology with tuned transferrin receptor binding, designed to facilitate brain penetration and plaque removal while minimizing hematologic effects. In preclinical studies to date, AL137 has demonstrated robust brain uptake at low doses, supporting further advancement and the potential for low-dose, subcutaneous administration.

    AL050

    • Alector continues to progress AL050, its ABC-enabled engineered glucocerebrosidase (GCase) enzyme replacement therapy (ERT) for PD, through preclinical development. The company is targeting submission of an IND application in 2027.



    • AL050 is designed to address key challenges associated with enzyme delivery to the brain, featuring an engineered GCase with improved activity and stability and a silenced effector function to maximize safety, paired with Alector's tunable ABC technology. Preclinical studies to date have demonstrated increased GCase activity and reduced toxic substrate accumulation, supporting its continued preclinical development as a potential therapy for PD and Lewy body dementia associated with GBA loss-of-function mutations.

    ABC siRNA Platform

    • Alector continues to advance its ABC-enabled siRNA platform, which is designed to enable peripheral dosing, offering the potential for more convenient administration compared with traditional intrathecal delivery.



    • Alector has selected lead candidate, AL064 for its ABC-enabled tau siRNA program for the treatment of AD and other tauopathies and is advancing it to IND-enabling studies.



    • In addition to AL064, the company is advancing early-stage siRNA programs toward lead candidate selection, including ADP062-ABC (PD), an alpha-synuclein siRNA, and ADP065-ABC (multiple neurodegenerative conditions), an NLRP3 siRNA, reflecting the broad applicability of the ABC platform across disease mechanisms.

    Progranulin Programs (nivisnebart (AL101/GSK4527226) and latozinemab (AL001)) in Collaboration with GSK

    Nivisnebart (AL101/GSK4527226)

    • The global, randomized, double blind, placebo-controlled PROGRESS-AD Phase 2 clinical trial of nivisnebart (AL101/GSK4527226) in early AD remains ongoing.



    • An independent interim futility analysis for the PROGRESS-AD trial is planned for the first half of 2026.



    • Nivisnebart is an investigational human monoclonal antibody designed to block and internalize the sortilin receptor, leading to increased levels of progranulin (PGRN) in the brain. It has pharmacokinetic and pharmacodynamic properties that may make it suitable for the potential treatment of more prevalent neurodegenerative diseases.

    Latozinemab (AL001)

    • Alector plans to present the results from the INFRONT-3 Phase 3 clinical trial at an upcoming scientific meeting in 1H 2026.

    Fourth Quarter 2025 Financial Results

    Revenue. Collaboration revenue for the quarter ended December 31, 2025, was $6.2 million, compared to $54.2 million for the same period in 2024. Collaboration revenue for the year ended December 31, 2025, was $21.0 million, compared to $100.6 million for the same period in 2024. The decrease in year-over-year collaborative revenue was primarily due to the satisfaction of the performance obligations associated with the AL002 program and the latozinemab FTD-C9orf72 Phase 2 trial in the fourth quarter of 2024, resulting in lower revenue recognized in 2025.

    R&D Expenses. Total research and development expenses for the quarter ended December 31, 2025, were $32.5 million, compared to $46.5 million for the same period in 2024. Total research and development expenses for the year ended December 31, 2025, were $123.1 million compared to $185.9 million for the same period in 2024. The decrease in year-over-year R&D expenses was mainly due to a decrease in research and development expenses for the AL002 program as well as a decrease in personnel related costs as a result of the reductions in force.

    G&A Expenses. Total general and administrative expenses for the quarter ended December 31, 2025, were $13.3 million compared to $15.0 million for the same period in 2024. Total general and administrative expenses for the year ended December 31, 2025, were $54.0 million compared to $59.6 million for the same period in 2024. The decrease in year-over-year G&A expenses was primarily due to a decrease in personnel related costs as a result of the reductions in force.

    Net Loss. For the quarter ended December 31, 2025, Alector reported a net loss of $37.3 million, or $0.34 net loss per share, compared to a net loss of $2.1 million, or $0.02 net loss per share, for the same period in 2024. For the year ended December 31, 2025, Alector reported a net loss of $142.9 million or $1.39 net loss per share, compared to a net loss of $119.0 million or $1.23 net loss per share, for the same period in 2024.

    Cash Position. Cash, cash equivalents, and investments were $256.0 million as of December 31, 2025. Management expects that this will be sufficient to fund current operations at least through 2027.

    About Alector

    Alector is a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, such as Alzheimer's disease, Parkinson's disease, and frontotemporal dementia. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, research and preclinical pipeline, blood-brain barrier technology platform, planned and ongoing preclinical studies and clinical trials, anticipated timing of and detail regarding release of data for PROGRESS-AD, expected milestones, expectations of our collaborations and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, with the Securities and Exchange Commission ("SEC"), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector's forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.



    Selected Consolidated Balance Sheet Data

    (in thousands)

     
     December 31,

    2025
     December 31,

    2024
        
          
    Cash, cash equivalents, and marketable securities$256,024 $413,397
    Total assets 293,237  468,303
    Total current liabilities (excluding deferred revenue) 62,819  101,396
    Deferred revenue (including current portion) 171,221  195,832
    Total liabilities 262,588  341,503
    Total stockholders' equity 30,649  126,800



    Consolidated Statement of Operations Data

    (in thousands, except share and per share data)

     
      Three Months Ended

    December 31,
      Twelve Months Ended

    December 31,
      2025   2024   2025   2024 
    Collaboration revenue $6,237   $54,240   $21,045   $100,558 
    Operating expenses:           
    Research and development  32,463    46,461    123,065    185,940 
    General and administrative  13,340    15,028    53,987    59,615 
    Total operating expenses  45,803    61,489    177,052    245,555 
    Loss from operations  (39,566)   (7,249)   (156,007)   (144,997)
    Other income, net  2,467    5,223    13,246    26,076 
    Net loss before income tax  (37,099)   (2,026)   (142,761)   (118,921)
    Income tax expense  168    48    168    128 
    Net loss $(37,267)  $(2,074)  $(142,929)  $(119,049)
    Net loss per share, basic and diluted $(0.34)  $(0.02)  $(1.39)  $(1.23)
    Shares used in computing net loss per share basic and diluted  109,521,640    98,319,416    102,998,978    96,588,177 



    Alector Contacts:


    Argot Partners (media)

    David Rosen

    (212) 600-1494

    [email protected]

    Argot Partners (investors)

    Laura Perry

    (212) 600-1902

    [email protected]



    Primary Logo

    Get the next $ALEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALEC

    DatePrice TargetRatingAnalyst
    10/22/2025$1.50Outperform → Neutral
    Mizuho
    10/22/2025Buy → Hold
    TD Cowen
    10/22/2025Overweight → Neutral
    Cantor Fitzgerald
    10/22/2025Outperform → Mkt Perform
    William Blair
    10/22/2025Buy → Neutral
    BTIG Research
    7/28/2025$3.50Neutral → Outperform
    Mizuho
    12/17/2024$9.00 → $2.50Outperform → Neutral
    Mizuho
    12/16/2024$4.00Buy → Hold
    Stifel
    More analyst ratings

    $ALEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alector downgraded by Mizuho with a new price target

    Mizuho downgraded Alector from Outperform to Neutral and set a new price target of $1.50

    10/22/25 7:10:52 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector downgraded by TD Cowen

    TD Cowen downgraded Alector from Buy to Hold

    10/22/25 7:10:36 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Alector from Overweight to Neutral

    10/22/25 7:10:36 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    SEC Filings

    View All

    SEC Form S-8 filed by Alector Inc.

    S-8 - Alector, Inc. (0001653087) (Filer)

    2/25/26 4:20:43 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Alector Inc.

    10-K - Alector, Inc. (0001653087) (Filer)

    2/25/26 4:15:52 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alector, Inc. (0001653087) (Filer)

    2/25/26 4:10:26 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Wong-Sarad Grace sold $5,751 worth of shares (4,753 units at $1.21), decreasing direct ownership by 4% to 122,982 units (SEC Form 4)

    4 - Alector, Inc. (0001653087) (Issuer)

    12/8/25 6:03:36 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Alector Inc.

    4 - Alector, Inc. (0001653087) (Issuer)

    12/3/25 9:07:19 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Rosenthal Arnon sold $116,827 worth of shares (104,347 units at $1.12), decreasing direct ownership by 4% to 2,420,040 units (SEC Form 4)

    4 - Alector, Inc. (0001653087) (Issuer)

    12/3/25 9:06:26 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer's Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer's Disease) Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer's disease expected in the first half of 2026 $256.0 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Alector, Inc.

    2/25/26 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector to Participate in the TD Cowen 46th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a corporate presentation at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 pm ET. A live webcast of the corporate presentation will be available on the "Events & Presentations" page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event. About AlectorAlector is a clini

    2/24/26 8:00:00 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

    SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector's Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO. "Neil has demonstrated exceptional leadership, judgment, strategic insight, and an unwavering commitment to Alector's mission," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "His

    12/12/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Leadership Updates

    Live Leadership Updates

    View All

    Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

    SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector's Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO. "Neil has demonstrated exceptional leadership, judgment, strategic insight, and an unwavering commitment to Alector's mission," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "His

    12/12/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector Reports First Quarter 2024 Financial Results and Provides Business Update

    Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 202

    5/8/24 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022. "We are delighted to welcome Gary to our executive leadership tea

    3/29/22 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Financials

    Live finance-specific insights

    View All

    Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

    On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease expected to complete in 2026 Continuing to progress Alector Brain Carrier programs, including the company's anti-amyloid beta antibody, engineered GCase enzyme replacement therapy, and anti-tau siRNA $307.3 million in cash, cash equivalents, and investments provides runway into the second half of 2027 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NE

    8/7/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

    SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2025, and provide a mid-year business update. The call will feature remarks from Ryan Darby, M.D., Associate Professor of Neurology and Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center, who will speak on the unmet need in frontotemporal dementia. A press release deta

    7/31/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates, including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company

    2/26/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alector Inc.

    SC 13G - Alector, Inc. (0001653087) (Subject)

    12/6/24 5:30:28 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alector Inc.

    SC 13G/A - Alector, Inc. (0001653087) (Subject)

    11/12/24 7:21:57 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alector Inc.

    SC 13G/A - Alector, Inc. (0001653087) (Subject)

    11/7/24 12:41:31 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care